Date: 2016-05-26
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the International Society for Cell Therapy (ISCT) 2016 Annual Meeting, held from May 25 to 28, 2016, in Singapore
Company: Txcell (France)
Product: OvaSave® (antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy)
Action
mechanism:
- cell therapy/immunotherapy product. OvaSave® is an antigen-specific type 1 regulatory T (Ag-Treg) cell based immunotherapy. The Ag-Treg cells utilized in Ovasave® are isolated from whole blood of the patient, activated by the specific antigen, ovalbumin. The cloned Ag-Treg cells are expanded ex vivo before their reinjection into that same patient. The injected Ag-Treg cells home to sites of inflammation and are activated locally by the specific food antigen, ovalbumin.
Disease:
Therapeutic
area:
Country:
Trial
details:
Latest
news:
- • On May 26, 2016, TxCell announced the presentation of novel mechanism of action data for its lead drug candidate Ovasave®, as well as latest results from TxCell’s second technology platform, ENTrIA. The data will be divulged at two poster presentations at the International Society for Cell Therapy (ISCT) 2016 Annual Meeting, held from May 25 to 28, 2016, in Singapore. Miguel Forte, Chief Operating Officer of TxCell and Chief Commercialization Officer of the ISCT, will contribute to the annual meeting alongside two scientists from his department at TxCell, Nathalie Belmonte and Julie Gertner-Dardenne. The two posters to be presented by TxCell at the ISCT 2016 Annual Meeting are:
‘Clinical efficiency of antigen-specific Tregs linked to invasive potential through lytic molecule expression’ (poster N°176). Julie Gertner-Dardenne will present the results of her TxCell research team studying the mechanism of action of TxCell’s lead drug candidate Ovasave® based on clinical batches from the first-in-man Phase I/II CATS1 study. These analyses show a correlation between the expression of granzyme molecules and clinical efficacy. Granzyme molecules are proteins that are released by specific immune cells. They are critical to induce programmed cell death (apoptosis) and play an important role in the immune defense system against viruses, tumors and intracellular bacteria. Experiments recently performed at TxCell show that the role of granzyme molecules in the Ovasave® mechanism involves mainly cell invasion through degradation of the extracellular matrix proteins, in addition to their cytotoxic role.
‘Regulatory T cell engineered with Chimeric Antigen Receptor (CAR-Treg) for Inflammatory and Autoimmune diseases’ (poster N°162). Nathalie Belmonte will present results obtained with ENTrIA, TxCell’s second technology platform, composed of Chimeric Antigen Receptor engineered FoxP3+ Regulatory T cells (CAR-Treg). TxCell’s results demonstrate that extracellular macromolecules are able to trigger CAR mediated intracellular signalling in Treg cells. These data demonstrate that, in addition to surface bound molecular entities such as CD19 used for CAR-T cell activation in cancer, extracellular macromolecules can be suitable for triggering CAR activation on Treg cells. These extracellular macromolecules can be used to induce the local activation of CARTreg cells for the treatment of auto-immune and inflammatory diseases.
Is
general: Yes
